Literature DB >> 19877135

C-peptide an adequate endpoint in type 1 diabetes.

Johnny Ludvigsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19877135     DOI： 10.1002/dmrr.1035

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN： 1520-7552            Impact factor:   4.876


× No keyword cloud information.
  5 in total

1.  Immune intervention in children with type 1 diabetes.

Authors:  Johnny Ludvigsson
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

Review 2.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

3.  β Cells Persist in T1D Pancreata Without Evidence of Ongoing β-Cell Turnover or Neogenesis.

Authors:  Carol J Lam; Daniel R Jacobson; Matthew M Rankin; Aaron R Cox; Jake A Kushner
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

4.  Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment.

Authors:  O Kordonouri; E Pankowska; B Rami; T Kapellen; R Coutant; R Hartmann; K Lange; M Knip; T Danne
Journal:  Diabetologia       Date:  2010-08-14       Impact factor: 10.122

Review 5.  Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Authors:  Johnny Ludvigsson
Journal:  Drugs       Date:  2016-02       Impact factor: 11.431
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.